Acute Behavioral Toxicity of Pyridostigmine or Soman in Primates
Effects of a peripherally active carbamate (pyridostigmine bromide) and a centrally active organophosphate (OP) nerve agent (soman) on performance by rhesus monkeys of a compensatory tracking (primate equilibrium platform, or PEP) task were measured using a balanced Latin-square design to determine...
Saved in:
Published in | Toxicology and applied pharmacology Vol. 126; no. 2; pp. 311 - 318 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
San Diego, CA
Elsevier Inc
01.06.1994
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Effects of a peripherally active carbamate (pyridostigmine bromide) and a centrally active organophosphate (OP) nerve agent (soman) on performance by rhesus monkeys of a compensatory tracking (primate equilibrium platform, or PEP) task were measured using a balanced Latin-square design to determine the ED50 for pyridostigmine (0.66 mg/kg) and the up-and-down (titration) method to determine the ED50 for soman (2.50 μg/kg). We concluded that the PEP performance model is a sensitive and reliable indicator of anticholinesterase (anti-ChE) behavioral toxicity. We also found that soman, an irreversible inhibitor of acetylcholinesterase (AChE), is more than 100 times more behaviorally disruptive than the reversible peripheral inhibitor pyridostigmine, as indicated by the difference in ED50 doses expressed in molar terms. Soman′s behavioral toxicity is severe at levels of serum cholinesterase inhibition (70-80%) at which pyridostigmine does not significantly affect performance. As a prophylactic treatment for OP agent poisoning, pyridostigmine has a substantial safety factor, since behavioral toxicity becomes significant only at approximately four times the proposed therapeutic dose. |
---|---|
AbstractList | Effects of a peripherally active carbamate (pyridostigmine bromide) and a centrally active organophosphate (OP) nerve agent (soman) on performance by rhesus monkeys of a compensatory tracking (primate equilibrium platform, or PEP) task were measured using a balanced Latin-square design to determine the ED50 for pyridostigmine (0.66 mg/kg) and the up-and-down (titration) method to determine the ED50 for soman (2.50 micrograms/kg). We concluded that the PEP performance model is a sensitive and reliable indicator of anticholinesterase (anti-ChE) behavioral toxicity. We also found that soman, an irreversible inhibitor of acetylcholinesterase (AChE), is more than 100 times more behaviorally disruptive than the reversible peripheral inhibitor pyridostigmine, as indicated by the difference in ED50 doses expressed in molar terms. Soman's behavioral toxicity is severe at levels of serum cholinesterase inhibition (70-80%) at which pyridostigmine does not significantly affect performance. As a prophylactic treatment for OP agent poisoning, pyridostigmine has a substantial safety factor, since behavioral toxicity becomes significant only at approximately four times the proposed therapeutic dose. Effects of a peripherally active carbamate (pyridostigmine bromide) and a centrally active organophosphate (OP) nerve agent (soman) on performance by rhesus monkeys of a compensatory tracking (primate equilibrium platform, or PEP) task were measured using a balanced Latin-square design to determine the ED50 for pyridostigmine (0.66 mg/kg) and the up-and-down (titration) method to determine the ED50 for soman (2.50 μg/kg). We concluded that the PEP performance model is a sensitive and reliable indicator of anticholinesterase (anti-ChE) behavioral toxicity. We also found that soman, an irreversible inhibitor of acetylcholinesterase (AChE), is more than 100 times more behaviorally disruptive than the reversible peripheral inhibitor pyridostigmine, as indicated by the difference in ED50 doses expressed in molar terms. Soman′s behavioral toxicity is severe at levels of serum cholinesterase inhibition (70-80%) at which pyridostigmine does not significantly affect performance. As a prophylactic treatment for OP agent poisoning, pyridostigmine has a substantial safety factor, since behavioral toxicity becomes significant only at approximately four times the proposed therapeutic dose. |
Author | Murphy, M.R. Fanton, J.W. Hartgraves, S.L. Brown, G.C. Blick, D.W. Yochmowitz, M.G. |
Author_xml | – sequence: 1 givenname: D.W. surname: Blick fullname: Blick, D.W. – sequence: 2 givenname: M.R. surname: Murphy fullname: Murphy, M.R. – sequence: 3 givenname: G.C. surname: Brown fullname: Brown, G.C. – sequence: 4 givenname: M.G. surname: Yochmowitz fullname: Yochmowitz, M.G. – sequence: 5 givenname: J.W. surname: Fanton fullname: Fanton, J.W. – sequence: 6 givenname: S.L. surname: Hartgraves fullname: Hartgraves, S.L. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4130108$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/8209384$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kEtPAkEQhCcGg4BevZnswetiNzv7mJtIfCUkkoiJt808enUM7JCZhci_dzcQbp76UF91qmrIerWribFrhDECZHeNlJsxCsHHiBM8YwMEkcWQJEmPDQA4xgDF5wUbhvADAIJz7LN-MQGRFHzA7qd621D0QN9yZ52Xq2jpfq22zT5yVbTYe2tcaOzX2tYUOR-9u7WsI1tHC2_XsqFwyc4ruQp0dbwj9vH0uJy9xPO359fZdB5rnvAmTkmBMsLgRJJKU8x0jpDnQimVcakNYkUVaJFLAZQbw02RaYU5z_JCZVmajNj48Fd7F4Knqtx0Cfy-RCi7JcpuibJbouyWaA03B8Nmq9ZkTvixeqvfHnUZtFxVXtbahhPGMQGEosWKA0ZtuZ0lXwZtqdZkrCfdlMbZ_xL8AdS2e6U |
CODEN | TXAPA9 |
CitedBy_id | crossref_primary_10_1016_0091_3057_94_90062_0 crossref_primary_10_1016_S0091_3057_01_00596_2 crossref_primary_10_1002_jat_1210 crossref_primary_10_1016_j_saa_2018_11_011 crossref_primary_10_1038_nm1296_1382 crossref_primary_10_1139_cjpp_2014_0113 crossref_primary_10_1016_0091_3057_94_90326_3 crossref_primary_10_1207_S15327876MP1402_4 crossref_primary_10_2174_1573412915666190715094347 crossref_primary_10_5155_eurjchem_6_3_350_356_1283 crossref_primary_10_1093_chromsci_bmz043 crossref_primary_10_1006_taap_1997_8160 crossref_primary_10_1016_S0161_813X_02_00005_0 crossref_primary_10_1016_j_toxrep_2021_04_005 crossref_primary_10_1254_jjp_79_25 crossref_primary_10_1371_journal_pone_0222197 crossref_primary_10_1080_10826070701540605 crossref_primary_10_3109_15569543_2014_994131 crossref_primary_10_1016_j_ntt_2005_06_015 |
ContentType | Journal Article |
Copyright | 1994 Academic Press 1994 INIST-CNRS |
Copyright_xml | – notice: 1994 Academic Press – notice: 1994 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1006/taap.1994.1121 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1096-0333 |
EndPage | 318 |
ExternalDocumentID | 10_1006_taap_1994_1121 8209384 4130108 S0041008X84711215 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Journal Article |
GroupedDBID | --- --K --M .55 .GJ .HR .~1 0R~ 123 1B1 1RT 1~. 1~5 29Q 3O- 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKC AAIKJ AAKOC AALRI AAMNW AAOAW AAQFI AAQXK AATCM AAXUO ABEFU ABFNM ABFRF ABFYP ABJNI ABLST ABMAC ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AFFNX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHEUO AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AKIFW ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLECG BLXMC C45 CAG COF CS3 DM4 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KCYFY KOM LG5 M33 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SPT SSJ SSP SSZ T5K TEORI TWZ UHS WH7 WUQ X7M XJT XPP Y6R YCJ ZGI ZKB ZMT ZU3 ZXP ~G- ~KM 08R AAPBV AAUGY ABPIF ABPTK IQODW AAXKI AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX ACRPL ADNMO CITATION |
ID | FETCH-LOGICAL-c434t-5eb0bd9d12aeb5516c710779bbb64acd11fef0c97a90e7dd4d86cb174678b6653 |
ISSN | 0041-008X |
IngestDate | Fri Dec 06 01:20:01 EST 2024 Sat Sep 28 07:35:46 EDT 2024 Sun Oct 29 17:07:06 EDT 2023 Fri Feb 23 02:27:28 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Nervous system diseases Toxicity Acute Monkey Tracking task Organic carbamate Vertebrata Mammalia Animal Primates Organophosphorus compounds Anticholinesterase agent Behavior Soman Carbamate Comparative study |
Language | English |
License | CC BY 4.0 https://www.elsevier.com/tdm/userlicense/1.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c434t-5eb0bd9d12aeb5516c710779bbb64acd11fef0c97a90e7dd4d86cb174678b6653 |
PMID | 8209384 |
PageCount | 8 |
ParticipantIDs | crossref_primary_10_1006_taap_1994_1121 pubmed_primary_8209384 pascalfrancis_primary_4130108 elsevier_sciencedirect_doi_10_1006_taap_1994_1121 |
PublicationCentury | 1900 |
PublicationDate | 1994-06-01 |
PublicationDateYYYYMMDD | 1994-06-01 |
PublicationDate_xml | – month: 06 year: 1994 text: 1994-06-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | San Diego, CA |
PublicationPlace_xml | – name: San Diego, CA – name: United States |
PublicationTitle | Toxicology and applied pharmacology |
PublicationTitleAlternate | Toxicol Appl Pharmacol |
PublicationYear | 1994 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
SSID | ssj0009441 |
Score | 1.5783566 |
Snippet | Effects of a peripherally active carbamate (pyridostigmine bromide) and a centrally active organophosphate (OP) nerve agent (soman) on performance by rhesus... |
SourceID | crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 311 |
SubjectTerms | Animals Behavior, Animal - drug effects Biological and medical sciences Chemical and industrial products toxicology. Toxic occupational diseases Cholinesterases - blood Dose-Response Relationship, Drug Macaca mulatta Male Medical sciences Pyridostigmine Bromide - toxicity Soman - toxicity Toxicology Various organic compounds |
Title | Acute Behavioral Toxicity of Pyridostigmine or Soman in Primates |
URI | https://dx.doi.org/10.1006/taap.1994.1121 https://www.ncbi.nlm.nih.gov/pubmed/8209384 |
Volume | 126 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLWge0GaEAwmBgz5AY0HlpAPx03eKAM2MQ1VW6f1LYo_okViTdVlGuPXc2_sxC1sEuwlSt0kTn2ur49d33MJeRtFqdIyFZ4O4tJjiYi9TIcxnmmRZHqoWkmho-_84JR9myZTt62ojS5phC9_3RpXch9UoQxwxSjZ_0C2fygUwDngC0dAGI7_hPFI4r_8n5Yi7euflbSbLMY3i0rVqKFxgUyyXrw_qXHBvgKvhxITjd09aJlpe6sTZCosO507aWsX-vDDpl__7J_5fyN25B_3pf0sf9_f852HkecX9XXVppKFy_d9t_ZgRIT58tpDHxSzsmcTJbw8oBZTM8QYvxrgXufYaF70jtfEylsLi5bcaGwdsLaf0ludPTgMQKgpijnGXDKMhgrdsNZvNjzBF8L3wYEYxTQekjWUTWQDsjY6PD47dCLNjJkMi_YHdCKfAf-wWstdJGZ9XlxC1ypNTpQ_ZiotY5k8IY_tVIOOjN08JQ_0bIPsjA2gN7t04kLvLnfpDh0vQb1B1s2CLjVxas_Ix9bYqDM22hkbrUu6amy0XtDW2Gg1o52xPSenX79M9g48m37DkyxmjZdoEQiVqTAqoNsmIZfARofDTAjBWSFVGJa6DGQ2LLIA-rRiKuVShJi_JhWcJ_EmGczqmX5BKC8iuFwlLd8NyiKDibAOZMpSLiKl0i3yrmvPfG5UVnKjp81zbPkcWz7Hlt8iYdfcueWIhvvlYBV33rO9gktfBRK4MIDaNw1O_RdAi7M4ZS_vUdkr8sj1lNdk0Cyu9Dbw1ka8seb2Gx57l8c |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+Behavioral+Toxicity+of+Pyridostigmine+or+Soman+in+Primates&rft.jtitle=Toxicology+and+applied+pharmacology&rft.au=Blick%2C+D.W.&rft.au=Murphy%2C+M.R.&rft.au=Brown%2C+G.C.&rft.au=Yochmowitz%2C+M.G.&rft.date=1994-06-01&rft.pub=Elsevier+Inc&rft.issn=0041-008X&rft.eissn=1096-0333&rft.volume=126&rft.issue=2&rft.spage=311&rft.epage=318&rft_id=info:doi/10.1006%2Ftaap.1994.1121&rft.externalDocID=S0041008X84711215 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-008X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-008X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-008X&client=summon |